Skip to main content
Premium Trial:

Request an Annual Quote

Finding New Purpose

Premium

A new study in Nature Medicine shows that the anti-depressant tranylcypromine — an MAO inhibitor sold commercially as Parnate — could be used as part of a combination therapy to treat acute myeloid leukemia, reports the PsychCentral blog. All-trans-retinoic acid is used to treat acute promyelocytic leukemia, but hasn't been effective for the more common types of AML, an incongruity that puzzled the researchers. Now, the team says, the new study shows that the molecular pathway that all-trans-retinoic acid targets is dormant in AML cells, which means the drugs have no target to attack and therefore don't work, PsychCentral says. But the tranylcypromine switches this pathway back on, making the cancer cells susceptible to the cancer treatment.

The team has started a Phase II clinical trial of this drug combination in AML patients, the blog adds.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.